Pancreatic Cancer Research

ResearcherKyushu UniversityActive in the last 2 years

Zilong Yan

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-3725-5125; OpenAlex author ID A5030400998. Sources: OpenAlex.

Their work

Papers
9 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
33
Papers, trials and grants by year

2017: 1 paper · 2018: none · 2019: 1 paper · 2020: 1 paper · 2021: 1 paper · 2022: none · 2023: 2 papers · 2024: 1 paper · 2025: 2 papers

Papers 9

  1. Identification of a NEK7-related pyroptosis gene signature against pancreatic cancer and evaluation of its potential in tumor microenvironment remodeling via r… First author DOI 10.1007/s10142-025-01597-y↗
  2. Identification of a dihydroartemisinin-related prognostic signature and its contribution to cancer associated fibroblast of the tumor microenvironment of pancr… Co-author DOI 10.1186/s12876-025-04241-y↗
  3. Effect of Bioactive Black Phosphorus Nanomaterials on Cancer-Associated Fibroblast Heterogeneity in Pancreatic Cancer. First author DOI 10.1021/acsnano.4c06147↗
  4. Involvement of angiogenesis in cancer-associated acinar-to-ductal metaplasia lesion of pancreatic cancer invasive front. Co-author DOI 10.1007/s00432-022-04554-5↗
  5. Identifying a baicalein-related prognostic signature contributes to prognosis prediction and tumor microenvironment of pancreatic cancer. Co-author DOI 10.3389/fimmu.2023.1223650↗
  6. NEK7 Promotes Pancreatic Cancer Progression And Its Expression Is Correlated With Poor Prognosis. Co-author DOI 10.3389/fonc.2021.705797↗
  7. LAMA4 upregulation is associated with high liver metastasis potential and poor survival outcome of Pancreatic Cancer. Co-author DOI 10.7150/thno.47001↗
  8. CD110 promotes pancreatic cancer progression and its expression is correlated with poor prognosis. Co-author DOI 10.1007/s00432-019-02860-z↗
  9. Primary Recurrence in the Lung is Related to Favorable Prognosis in Patients with Pancreatic Cancer and Postoperative Recurrence. Co-author DOI 10.1007/s00268-017-4068-6↗

Closest collaborators

The 25 strongest of 33 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Biao Zheng · 6 shared papers, 2017–2025 · strength 0.86
  2. Zhengquan Lai · 4 shared papers, 2023–2025 · strength 0.85
  3. Jianhua Qu · 4 shared papers, 2021–2025 · strength 0.80
  4. Citing Zhang · 3 shared papers, 2023–2025 · strength 0.65
  5. Jikui Liu · 3 shared papers, 2021–2024 · strength 0.50
  6. Jinglin Lai · 2 shared papers, 2025 · strength 0.48
  7. Kenoki Ohuchida · 4 shared papers, 2017–2023 · strength 0.41
  8. Masafumi Nakamura · 3 shared papers, 2017–2023 · strength 0.33
  9. Takao Ohtsuka · 3 shared papers, 2017–2020 · strength 0.25
  10. Jia Liu · 1 shared paper, 2025 · strength 0.25
  11. Xueqing Liu · 1 shared paper, 2025 · strength 0.25
  12. Chika Iwamoto · 2 shared papers, 2019–2023 · strength 0.24
  13. Yoshinao Oda · 2 shared papers, 2019–2023 · strength 0.24
  14. Kohei Nakata · 2 shared papers, 2019–2023 · strength 0.24
  15. Shengyong Geng · 1 shared paper, 2024 · strength 0.20
  16. Takashi Okumura · 2 shared papers, 2017–2019 · strength 0.16
  17. Shin Kibe · 1 shared paper, 2023 · strength 0.16
  18. Bo Zhang · 1 shared paper, 2023 · strength 0.16
  19. Toshiya Abe · 1 shared paper, 2023 · strength 0.16
  20. Noboru Ideno · 1 shared paper, 2023 · strength 0.16
  21. Naoki Ikenaga · 1 shared paper, 2023 · strength 0.16
  22. Tomohiko Shinkawa · 1 shared paper, 2023 · strength 0.16
  23. Shuang Fei · 1 shared paper, 2023 · strength 0.16
  24. Daiki Eguchi · 1 shared paper, 2020 · strength 0.09
  25. Peng Liu · 1 shared paper, 2020 · strength 0.09

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.